Aging-related colonic dysmotility stems primarily from clonal expansion of somatic mtDNA mutations in myenteric neurons, triggering a senescence cascade via minority mitochondrial outer membrane permeabilization (miMOMP) rather than apoptosis. This hypothesis posits that mtDNA mutation burden, not nuclear genome decay, is the rate-limiting step in myenteric plexus aging, making it the critical target for interventions.

Mechanistic Proposal Post-mitotic myenteric neurons accumulate mtDNA mutations at rates ~70-fold higher than nuclear DNA, due to proximity to ROS and lack of histones [https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2021.805126/full]. Heteroplasmic variants in key respiratory chain genes (e.g., MT-ND4, MT-CO1) disrupt oxidative phosphorylation, creating bioenergetic deficits and ROS bursts. This triggers miMOMP—localized mitochondrial permeabilization releasing cytochrome c without full apoptosis, activating caspase-2 and p53/p21 pathways to induce cellular senescence [https://pmc.ncbi.nlm.nih.gov/articles/PMC10253713/]. In myenteric ganglia, senescent neurons secrete SASP factors, propagating dysfunction to neighboring cells and stem cells, explaining the 38-60% neuron loss seen in aging [https://pubmed.ncbi.nlm.nih.gov/20878508/].

Why this over apoptosis? Myenteric neurons are metabolically demanding but irreplaceable; senescence may be a failed protective response to partial mtDNA damage, preserving cells short-term but causing chronic inflammation and dysmotility long-term. The threshold effect post-age 70 in humans aligns with mutation load reaching ~60-80% heteroplasmy in critical neurons, tipping miMOMP events into a tissue-level senescent state [https://pmc.ncbi.nlm.nih.gov/articles/PMC12727128/].

Evidence Synthesis and Novel Insight Current data shows mtDNA mutations correlate with aging phenotypes, but causation is unproven. The gap: no one has sequenced mtDNA from sorted myenteric neurons while quantifying senescence markers like p16^Ink4a or SASP factors. Mitochondrial-targeted antioxidants extend lifespan by reducing ROS, supporting mtDNA as a driver [https://pmc.ncbi.nlm.nih.gov/articles/PMC3843653/], but they don’t address mutation accumulation.

Novel angle: Vulnerability is neuron-subtype specific. Nitrergic neurons, with high basal oxidative metabolism, may accumulate mutations faster, leading to selective loss and constipation dominance in aging. This could explain why some individuals retain motility despite age—lower initial mutation load or better mitochondrial biogenesis. Nuclear genome interventions (e.g., CRISPR editing nuclear longevity genes) fail because they don’t reset mtDNA mutation clocks; it’s like patching software while the hardware is corrupt.

Testable Predictions

1. Direct Causation: Use mito-CRISPR base editing in mouse myenteric neurons to introduce pathogenic mtDNA variants (e.g., m.8344A>G). Predict: accelerated senescence (p16^Ink4a upregulation), colonic dysmotility within months, reversible with mitochondrial-targeted antioxidants or mtDNA gene therapy.
2. Senescence Cascade: Single-cell RNA-seq of aged myenteric plexus will show senescent neuron clusters with high mtDNA mutation burden, expressing SASP genes (IL-6, TNF-α). Blocking senescence via senolytics (dasatinib/quercetin) should restore motility without clearing mutations.
3. Threshold Effect: Longitudinal sequencing of mtDNA from human colonic biopsies (via endoscopy) will show mutation load >70% heteroplasmy correlating with constipation symptoms, not just age.

Counterarguments and Falsifiability Critics might argue nuclear genome epigenetic changes drive aging. Falsification: If nuclear reprogramming (e.g., Yamanaka factors) rejuvenates myenteric neurons without reducing mtDNA mutation load, the hypothesis fails. Similarly, if mtDNA mutation-free aged mice (e.g., with enhanced mtDNA repair) still show neuron loss, other factors dominate.

Implications If true, aging interventions must pivot to mtDNA—via gene drives, allotopic expression, or clonal expansion inhibitors. This redefines “successful aging” as managing the mitochondrial genome, not just the nuclear one. The myenteric plexus becomes a model for tissue-specific mtDNA pathology, with motility serving as a readout for mitochondrial health.